

MARKET REPORT



Ulcerative Colitis - Pipeline Review, H2 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Ulcerative Colitis - Pipeline Review, H2 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Ulcerative Colitis - Pipeline Review, H2 2017

Ulcerative Colitis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2017, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 37, 26, 1, 50, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC9794IDB

Number of Pages : 433

Report Format : PDF

Publisher Information :



Table Of Contents for Ulcerative Colitis - Pipeline Review, H2 2017

- Table of Contents 2
Introduction 6
Ulcerative Colitis - Overview 7
Ulcerative Colitis - Therapeutics Development 8
Ulcerative Colitis - Therapeutics Assessment 27
Ulcerative Colitis - Companies Involved in Therapeutics Development 41
Ulcerative Colitis - Drug Profiles 83
Ulcerative Colitis - Dormant Projects 397
Ulcerative Colitis - Discontinued Products 404
Ulcerative Colitis - Product Development Milestones 406
Appendix 416

How to Buy...

Ulcerative Colitis - Pipeline Review, H2 2017

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/130956>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$1700** | Single User Price
- \$3400** | Site License Price
- \$5100** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.